ATE457308T1 - Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta - Google Patents

Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta

Info

Publication number
ATE457308T1
ATE457308T1 AT04759766T AT04759766T ATE457308T1 AT E457308 T1 ATE457308 T1 AT E457308T1 AT 04759766 T AT04759766 T AT 04759766T AT 04759766 T AT04759766 T AT 04759766T AT E457308 T1 ATE457308 T1 AT E457308T1
Authority
AT
Austria
Prior art keywords
estrogen receptor
receptor beta
selective antagonists
substituted benzopyrans
substituted
Prior art date
Application number
AT04759766T
Other languages
English (en)
Inventor
Gregory Durst
Bryan Norman
Lance Pfeifer
Timothy Richardson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE457308T1 publication Critical patent/ATE457308T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
AT04759766T 2003-04-21 2004-04-08 Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta ATE457308T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46440503P 2003-04-21 2003-04-21
PCT/US2004/009271 WO2004094401A1 (en) 2003-04-21 2004-04-08 Substituted benzopyrans as selective estrogen receptor-beta agonists

Publications (1)

Publication Number Publication Date
ATE457308T1 true ATE457308T1 (de) 2010-02-15

Family

ID=33310883

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04759766T ATE457308T1 (de) 2003-04-21 2004-04-08 Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta

Country Status (6)

Country Link
US (1) US7279499B2 (de)
EP (1) EP1618102B1 (de)
AT (1) ATE457308T1 (de)
DE (1) DE602004025460D1 (de)
ES (1) ES2338119T3 (de)
WO (1) WO2004094401A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1626974B1 (de) * 2003-04-21 2008-08-27 Eli Lilly And Company Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
JP2008512458A (ja) 2004-09-07 2008-04-24 ワイス 6H−[1]ベンゾピラノ[4,3−b]キノリン及びエストロゲン様物質としてのそれらの使用
ATE504582T1 (de) * 2004-10-18 2011-04-15 Lilly Co Eli Substituierte benzopyrane als selektive östrogenrezeptor-beta-agonisten
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
US8093302B2 (en) 2005-02-15 2012-01-10 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-β agonists
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
AR056695A1 (es) * 2005-10-17 2007-10-17 Wyeth Corp Tetrahidroquinolinas, su sintesis e intermediarios
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
KR101638035B1 (ko) 2007-01-22 2016-07-11 지티엑스, 인코포레이티드 핵 수용체에 결합하는 물질
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
WO2010011605A2 (en) 2008-07-21 2010-01-28 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
WO2011014516A1 (en) 2009-07-28 2011-02-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Estrogen antagonists as treatments for sclerosing disorders
JP2013505262A (ja) * 2009-09-17 2013-02-14 バンダービルト ユニバーシティー mGluR5ネガティブアロステリックモジュレータとしての置換ヘテロアリールアミンカルボキサミド類似体、ならびに、その形成方法および使用方法
WO2015077246A1 (en) 2013-11-19 2015-05-28 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mglur5
AU2014353006B2 (en) 2013-11-20 2019-04-04 Signalchem Life Sciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
CN105960236A (zh) 2013-12-05 2016-09-21 卡罗医药股份公司 用于治疗间皮瘤的雌激素受体β激动剂
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
EP3478269A4 (de) 2016-06-29 2020-04-08 Otonomy, Inc. Triclyceridformulierungen für das ohr und verwendungen davon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0935000A3 (de) 1995-09-08 1999-09-08 Karo Bio Ab Waisenrezeptor
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
CA2396059A1 (en) 1999-12-30 2001-07-12 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US7214706B2 (en) 2000-03-01 2007-05-08 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
ES2293986T3 (es) 2000-03-27 2008-04-01 N.V. Organon Compuestos no esteroides tetraciclicos para tratamientos relacionados con el estrogeno.
GB2361642A (en) 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
DE60220179T2 (de) 2001-11-19 2008-02-07 Eli Lilly And Co., Indianapolis Substituierte benzopyrane als selektive agonisten am östrogenrezeptor-beta
TWI306450B (en) 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
US6630508B1 (en) 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists

Also Published As

Publication number Publication date
ES2338119T3 (es) 2010-05-04
US20060199858A1 (en) 2006-09-07
EP1618102A1 (de) 2006-01-25
US7279499B2 (en) 2007-10-09
EP1618102B1 (de) 2010-02-10
WO2004094401A1 (en) 2004-11-04
DE602004025460D1 (de) 2010-03-25

Similar Documents

Publication Publication Date Title
DE602004025460D1 (de) Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
IL185867A0 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
CY1110443T1 (el) Υποκατεστημενα βενζοπυρανια ως εκλεκτικοι αγωνιστες υποδοχεα-βητα οιστρογονων
YU51703A (sh) Derivati benzimidazola i piridilimidazola kao veznici za gaba receptore
EA200501430A1 (ru) Лиганды каннабиноидных рецепторов и их применение
DE60107687D1 (de) Cyclpentanoindole, mischungen derartige verbindungen enthaltend und behandlungsmethoden
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
PL2444085T3 (pl) Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka
ATE292118T1 (de) Pyrazolderivative als p-38 map kinase inhibitoren
PT925301E (pt) Derivados altamente lipofilos de camptotecina
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
DE60221425D1 (de) Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase-inhibitoren
PT1165544E (pt) 1,4-di-hidroindeno¬1,2-c|pirazoles substituidos como inibidores de tirosina-quinase
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
ATE296818T1 (de) Substituierte 6h-dibenzo(c,h)chromene als oestrogene agentien
JOP20220356B1 (ar) مشتقات تترازول كمثبطات لـ trpa1
ATE373000T1 (de) Pyrazolopyridin-derivate als antiherpesmittel
JOP20220350A1 (ar) مشتقات تترازول كمثبطات لـ trpa1
MY117975A (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
MY120281A (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
ATE394386T1 (de) 2-phenylpyran-4-on-derivate als selektive cox-2 inhibitoren
MX2007003307A (es) 4-bencil-1,3-dihidro-imidazol-2-tionas substituidas y no substituidas que actuan como agonistas adrenergicos alfa2 especificos o selectivos y metodos de uso de las mismas.
HN2001000165A (es) Derivados de imidazol
CY1114525T1 (el) (s)-n-methylnaltrexone,(μεθυλναλτρεξονη), διαδικασιες για την συνθεση της και η φαρμακευτικη της χρηση

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties